Topical bleaching agents, hydroquinone and tretinoin, remain the first-line published treatment for pigmentary skin concerns, with combination therapies considered for moderate-to-severe cases or first-line monotherapy non-responders. The triple-combination cream (TCC: hydroquinone 2-4% + tretinoin 0.05% + fluocinolone 0.01%) is the most-studied combination, but is used in 4-month courses with 2-month breaks to avoid steroid atrophy and hydroquinone-induced exogenous ochronosis (paradoxical darkening with prolonged unsupervised use).
Alternative agents for hydroquinone-intolerant patients or maintenance therapy:
- Tranexamic acid (oral 250 mg twice daily, 8-12 weeks), second/third-line for melasma + pigmentation; modulates melanocyte-keratinocyte interaction. Requires VTE risk screen.
- Cysteamine 5% cream, inferior to hydroquinone in head-to-head efficacy but well-tolerated alternative for mild-moderate cases.
- Thiamidol, newer tyrosinase inhibitor; emerging evidence for first-line use.
- Niacinamide 4%, kojic acid, ascorbic acid, meaningful pigment reduction with superior safety profiles; particularly useful in maintenance therapy.
- Glutathione, oral preferred over IV (see glutathione treatment page).
The IADVL framework is explicit: brightening protocols are dermatologist-led, time-bounded, and combined with mandatory iron-oxide SPF 50 photoprotection. Open-ended unsupervised hydroquinone use is the leading cause of exogenous ochronosis in Indian dermatology practice, and is precisely what DermaVue Kochi's structured pulse protocol prevents.
For melasma specifically: brightening is combined with low-fluence Q-switched Nd:YAG laser toning per the IJDVL protocol (1064 nm, 0.5-1 J/cm², 10 mm spot, 6-8 sessions at 2-week intervals).
